Zymeworks Common Price To Sales vs. EBITDA
| ZYME Stock | USD 14.09 0.33 2.29% |
Zymeworks Common Price To Sales Ratio |
|
For Zymeworks Common profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Zymeworks Common to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Zymeworks Common Stock utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Zymeworks Common's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Zymeworks Common Stock over time as well as its relative position and ranking within its peers.
Zymeworks |
Zymeworks Common's Revenue Breakdown by Earning Segment
Check out Your Current Watchlist.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zymeworks Common. If investors know Zymeworks will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zymeworks Common listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.49) | Revenue Per Share 0.831 | Quarterly Revenue Growth (0.03) | Return On Assets (0.15) | Return On Equity (0.29) |
The market value of Zymeworks Common Stock is measured differently than its book value, which is the value of Zymeworks that is recorded on the company's balance sheet. Investors also form their own opinion of Zymeworks Common's value that differs from its market value or its book value, called intrinsic value, which is Zymeworks Common's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zymeworks Common's market value can be influenced by many factors that don't directly affect Zymeworks Common's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zymeworks Common's value and its price as these two are different measures arrived at by different means. Investors typically determine if Zymeworks Common is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zymeworks Common's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Zymeworks Common Stock EBITDA vs. Price To Sales Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Zymeworks Common's current stock value. Our valuation model uses many indicators to compare Zymeworks Common value to that of its competitors to determine the firm's financial worth. Zymeworks Common Stock is rated below average in price to sales category among its peers. It is rated below average in ebitda category among its peers . At present, Zymeworks Common's Price To Sales Ratio is projected to decrease significantly based on the last few years of reporting. Comparative valuation analysis is a catch-all technique that is used if you cannot value Zymeworks Common by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Zymeworks EBITDA vs. Price To Sales
Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Zymeworks Common |
| = | 15.97 X |
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Zymeworks Common |
| = | (129.96 M) |
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Zymeworks EBITDA Comparison
Zymeworks Common is currently under evaluation in ebitda category among its peers.
Zymeworks Common Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Zymeworks Common, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Zymeworks Common will eventually generate negative long term returns. The profitability progress is the general direction of Zymeworks Common's change in net profit over the period of time. It can combine multiple indicators of Zymeworks Common, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -6.6 M | -6.9 M | |
| Operating Income | -138.1 M | -131.2 M | |
| Net Loss | -118.7 M | -112.7 M | |
| Income Before Tax | -119.2 M | -113.3 M | |
| Total Other Income Expense Net | 18.8 M | 19.8 M | |
| Net Income Applicable To Common Shares | 111.9 M | 117.5 M | |
| Net Loss | -118.7 M | -112.7 M | |
| Income Tax Expense | -568 K | -539.6 K | |
| Interest Income | 19.7 M | 20.7 M | |
| Net Interest Income | 19.7 M | 20.7 M | |
| Non Operating Income Net Other | 1.5 M | 1.4 M | |
| Change To Netincome | 4.3 M | 4.1 M | |
| Net Loss | (1.72) | (1.81) | |
| Income Quality | 1.00 | 0.52 | |
| Net Income Per E B T | 1.00 | 1.09 |
Zymeworks Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Zymeworks Common. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Zymeworks Common position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Zymeworks Common's important profitability drivers and their relationship over time.
Use Zymeworks Common in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Zymeworks Common position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Zymeworks Common will appreciate offsetting losses from the drop in the long position's value.Zymeworks Common Pair Trading
Zymeworks Common Stock Pair Trading Analysis
The ability to find closely correlated positions to Zymeworks Common could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Zymeworks Common when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Zymeworks Common - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Zymeworks Common Stock to buy it.
The correlation of Zymeworks Common is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Zymeworks Common moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Zymeworks Common Stock moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Zymeworks Common can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Zymeworks Common position
In addition to having Zymeworks Common in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Adviser Favorites Thematic Idea Now
Adviser Favorites
Financial advisors frequently recommend that individuals diversify their investment portfolios with a mix of different types of stocks. These can include blue-chip stocks, growth stocks, and dividend stocks. The Adviser Favorites theme has 17 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Adviser Favorites Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Your Current Watchlist. You can also try the Stocks Directory module to find actively traded stocks across global markets.
To fully project Zymeworks Common's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Zymeworks Common Stock at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Zymeworks Common's income statement, its balance sheet, and the statement of cash flows.